Axel Grothey MD
Director, GI Cancer Research, West Cancer Center, Germantown, TennesseeAxel Grothey, MD served as Associate Editor for PracticeUpdate Oncology from 2013-2021
Dr. Grothey is a medical oncologist and Director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, in Germantown, Tennessee.
Dr. Grothey received his medical degree at Ruhr-Universität Bochum, Germany, and completed residencies at West German Tumor Center and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Anderson Cancer Center at the University of Texas. He joined Mayo Clinic as a consultant in 2005 and was appointed as Professor of Oncology in 2007. He left Mayo Clinic in summer of 2018 to join West Cancer Center.
Dr. Grothey’s clinical interests focus on gastrointestinal cancers, in particular colorectal cancer, antiangiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently co-chairs the NCI Gastrointestinal Cancer Steering Committee after having served as chair of the NCI Colon Cancer Task Force for 6 years. Until June 2018 he was vice chair of the Gastrointestinal Cancer Committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He also chaired the Academic and Community Cancer Research United (ACCRU) international research network based at Mayo Clinic until he joined West Cancer Center.
He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology, and the Minnesota Medical Association.
Until 2018, Dr. Grothey was member of the NCCN Guidelines Committee for Colon, Rectal, and Anal Cancer. He is a member of the European Society of Medical Oncology (ESMO) guidelines committee for colorectal cancer.
In educational activities, Dr. Grothey is a six-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr. Grothey has given numerous international, national, and regional presentations, as well as invited and visiting professor presentations. He has co-authored more than 500 articles, books, book chapters, editorials, abstracts, and letters.
Positions:
Director of GI Cancer Research at West Cancer Center and Research Institute, Germantown, Tennessee
Degree:
MD: Ruhr-Universitat Bochum, Germany
Postgraduate Training:
Fellowship (hematology/oncology): University of Bochum
Research fellowship (biochemistry and molecular biology): MD Anderson Cancer Center, The University of Texas
Clinical Interests:
Colorectal cancer, anti-angiogenesis, signal transduction inhibitors, clinical trial design and statistics
Disclosures
The Mayo Clinic Foundation and West Clinic have received the following honoraria and grant support for activities conducted by Axel Grothey, MD:
Honoraria: Genentech/ Roche, Sanofi, Amgen, Eli-Lilly, Bayer, Bristol-Myers Squibb, Boston Biomedicals, Taiho, ARRAY.
Research grants: Genentech, Boston Biomedicals, ARRAY, Morphotek/ Eisai, Bayer, Sanofi, Daiichi, Merck.
Recent Contributions to PracticeUpdate:
- Entrectinib in Patients With Advanced or Metastatic NTRK Fusion–Positive Solid Tumors
- Kinase Inhibitors in the Management of Refractory Metastatic Colon Cancer
- Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib as First Treatment for Patients With Unresectable Hepatocellular Carcinoma
- 2019 Top Stories in Oncology: BEACON of Hope
- Capecitabine and Temozolomide vs FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
- ctDNA Analysis for Detection of MRD After Chemoradiotherapy for Localized Esophageal Cancer
- Efficacy of Pembrolizumab in Non-Colorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer
- Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma
- Circulating Tumor DNA Analyses as Prognostic Markers for Stage III Colon Cancer
- Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy